Greater Brisbane Clinical School, Faculty of Medicine, The University of Queensland, Northside Clinical Unit, The Prince Charles Hospital, Chermside, 4032, QLD, Australia.
Department of Cardiology, The Prince Charles Hospital, Chermside, 4032, QLD, Australia.
Eur Heart J Qual Care Clin Outcomes. 2023 Feb 28;9(2):150-160. doi: 10.1093/ehjqcco/qcac024.
Population studies reporting contemporary long-term outcomes following catheter ablation of atrial fibrillation (AF) are sparse.We evaluated long-term clinical outcomes following AF ablation and examined variation in outcomes by age, sex, and the presence of heart failure.
We identified 30 601 unique patients (mean age 62.7 ± 11.8 years, 30.0% female) undergoing AF ablation from 2008 to 2017 in Australia and New Zealand using nationwide hospitalization data. The primary outcomes were all-cause mortality and rehospitalizations for AF or flutter, repeat AF ablation, and cardioversion. Secondary outcomes were rehospitalizations for other cardiovascular events. During 124 858.7 person-years of follow-up, 1900 patients died (incidence rate 1.5/100 person-years) with a survival probability of 93.0% (95% confidence interval (CI) 92.6-93.4%) by 5 years and 84.0% (95% CI 82.4-85.5%) by 10 years. Rehospitalizations for AF or flutter (13.3/100 person-years), repeat ablation (5.9/100 person-years), and cardioversion (4.5/100 person-years) were common, with respective cumulative incidence of 49.4% (95% CI 48.4-50.4%), 28.1% (95% CI 27.2-29.0%), and 24.4% (95% CI 21.5-27.5%) at 10 years post-ablation. Rehospitalizations for stroke (0.7/100 person-years), heart failure (1.1/100 person-years), acute myocardial infarction (0.4/100 person-years), syncope (0.6/100 person-years), other arrhythmias (2.5/100 person-years), and new cardiac device implantation (2.0/100 person-years) occurred less frequently. Elderly patients and those with comorbid heart failure had worse survival but were less likely to undergo repeat ablation, while long-term outcomes were comparable between the sexes.
Patients undergoing AF ablations had good long-term survival, a low incidence of rehospitalizations for stroke or heart failure, and about half remained free of rehospitalizations for AF or flutter, including for repeat AF ablation, or cardioversion.
目前关于房颤(AF)导管消融后长期临床结局的人群研究较为少见。本研究评估了房颤消融后的长期临床结局,并考察了年龄、性别和心力衰竭对结局的影响。
我们利用澳大利亚和新西兰全国住院数据,从 2008 年至 2017 年确定了 30601 例(平均年龄 62.7±11.8 岁,30.0%为女性)接受房颤消融的患者。主要结局为全因死亡率以及房颤或房扑、再次房颤消融和电复律的再住院率。次要结局为其他心血管事件的再住院率。在 124858.7 人年的随访期间,有 1900 例患者死亡(发生率为 1.5/100 人年),5 年时的生存率为 93.0%(95%置信区间[CI] 92.6-93.4%),10 年时为 84.0%(95% CI 82.4-85.5%)。房颤或房扑(13.3/100 人年)、再次消融(5.9/100 人年)和电复律(4.5/100 人年)的再住院率较高,10 年后分别有 49.4%(95% CI 48.4-50.4%)、28.1%(95% CI 27.2-29.0%)和 24.4%(95% CI 21.5-27.5%)发生累积再住院。卒中(0.7/100 人年)、心力衰竭(1.1/100 人年)、急性心肌梗死(0.4/100 人年)、晕厥(0.6/100 人年)、其他心律失常(2.5/100 人年)和新心脏装置植入(2.0/100 人年)的再住院率较低。老年患者和合并心力衰竭的患者生存率较差,但再次消融的可能性较低,而两性之间的长期结局相当。
接受房颤消融的患者长期生存状况良好,卒中或心力衰竭的再住院率较低,约半数患者免于房颤或房扑再住院,包括再次房颤消融或电复律。